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Valorisation 
Since the introduction of radiotherapy for the treatment of cancer, more than hundred 
years ago, doctors have been trying to report treatments results as systematically and 
precisely as possible in order to learn about tumour as well as healthy tissue response 
to radiotherapy. The ultimate goal of radiotherapy is to eradicate the tumour without 
any lasting toxicity. In order to achieve this ambitious goal, several approaches are 
possible. 
One approach being subject of this thesis is reduction of the actual dose to the healthy 
tissue surrounding the tumour also known as the organs at risk (OARs). This reduction 
of dose can be achieved by using state of the art irradiation techniques such as 
intensity-modulated radiotherapy (IMRT) in which the intensity of the dose within the 
beam can be modulated resulting in an adequate dose to the tumour and an as low as 
possible dose to the OARs. Thanks to evolving technical possibilities, there are several 
ways to use IMRT in benefit of the patient, for example volumetric modulated arc 
technique (VMAT) and helical tomotherapy (TOMO). Another way to reduce dose to 
the OARs is using particle therapy instead of photon therapy, in which charged 
particles, for example protons and carbon ions, are used for irradiation. Due to specific 
characteristics of these particles the dose to surrounding healthy tissue can be reduced 
in some patients. Whether this reduction in dose to the OARs is clinically relevant has 
to be proven in time. Since proton therapy is becoming more and more available, 
although still on a small scale, the need for optimal patient selection becomes 
warranted since only a limited number of patients can be treated in such facilities. 
There are also extra costs involved with particle therapy compared to photon 
radiotherapy. This is why in silico studies are the logical first step to investigate whether 
a dosimetric advantage is achievable and effective. In Chapter 2 and 3 head and neck 
and low-grade glioma patients are included the two separate in silico trials conducted 
within the Radiation Oncology Collaborative Comparison (ROCOCO) consortium. These 
studies demonstrated the benefit of particle therapy through simulation instead of 
actual treatment. 
 
Thanks to these in silico trials, we know there is a dosimetric advantage for particle 
therapy, but it remains unsure whether this translates into a clinical benefit. To this 
end, an accurate prediction of the effect of radiation on various tissues is essential, 
such as the prediction of tumour response related to the delivered dose, also known as 
the tumour control probability (TCP). For many tumours, a higher dose is related to a 
better local control. This of course needs to be weighed against the inevitable exposure 
of the surrounding healthy tissue to radiation causing side effects, known as the normal 
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tissue complication probability (NTCP). Both TCP and NTCP are dependent on various 
patient-related factors of which some are not yet identified, especially in case of re-
irradiation, but also for central nervous system (CNS) side effects, specifically. When 
TCP and NTCP are known for each type of tissue (tumour and healthy tissue) a well-
balanced treatment choice can be made based on the risk of side effects versus the 
possibility of achieving local control of the tumour per treatment modality.  
Many different radiation centres started collecting dosimetric and toxicity data decades 
ago. Surprisingly, despite these great efforts in the past, there is still a desperate need 
for validated TCP and NTCP models, especially in the field of neuro-oncology. One of 
the reasons the collected data did not result in proper validation of such prediction 
models is because they lack uniformity of the actual collected data. It is therefore of 
great importance that the relevant CNS anatomical structures are identified and 
uniformly delineated in order to uniformly report the received dose related to 
registered side effects. For this a consensus-based delineation atlas, which includes all 
(potentially) relevant OARs, is needed. This thesis provides in this need by producing a 
European Particle Therapy Network (EPTN) consensus-based Neuro-Oncology Atlas 
including the posterior cerebellum (Chapter 4 and 5) as a new potentially relevant OAR. 
This neuro-oncology atlas will enable photon and particle radiotherapy centres within 
Europe and beyond to uniformly report on dose related toxicity for each specific OAR. 
Since manual delineation of OARs is one of the most time consuming task in 
radiotherapy planning and subject to inter- and intra-observer variability, there is a 
great interest in developing an automated delineation atlas. The CNS atlas presented in 
this thesis will serve as a base for this, e.g. for the Danish head and neck group 
(DAHANCA) and Danish brain oncology group (DNOG). 
When there is agreement on the relevant OARs and the structure names and 
delineation thereof, the next important issue is agreement on the dose each OAR 
tolerates without long-term toxicity, based on available literature. This agreement is 
important since the literature on tolerance dose is scarce, causing room for individual 
interpretation. This results in treatment plans being based on different, by radiation 
oncologists accepted doses in the OAR obstructing accurate treatment modality 
comparison. The latter is needed to upfront select the best treatment option for each 
individual patient. This thesis provides in this need by reaching this agreement by 
producing an EPTN consensus CNS Tolerance Table (Chapter 6). Both the CNS 
Delineation Atlas as well as the Tolerance Dose table are now incorporated into daily 
practice guidelines, as well as in trial protocols within and outside of the EPTN. 
 
This year, the first patient was treated with proton therapy in The Netherlands and 
health insurance companies together with the government and experts in the field of 
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radiotherapy will continue to work together to improve patient selection by collecting 
actual toxicity data in a mutual database. Collecting these data in a uniform matter will 
be the next challenging step. Especially for neuro oncology, were cognitive decline after 
radiotherapy is of great importance, uniform cognitive testing is needed, for example. 
As a result of chapter 4, 5 and 6, an EPTN expert group is now continuing previous work 
by producing a consensus on this toxicity registration. This will eventually result in the 
possibility to uniformly combine CNS dosimetric and toxicity data from all different 
centres throughout the world, enabling efficient cooperation between experts to 
produce and validate the needed NTCP models within the coming years. 
 
Another good example of cooperation leading to optimal treatment results is the 
treatment of epilepsy. Epilepsy in general is one of the most common severe 
neurological disorders. It is a disease in which patients have unexpected seizures 
making participation in daily family life and working processes challenging, which can 
have severe economic consequences. If the epilepsy is resistant to anti-epileptic drugs, 
resection of the epileptogenic region is an invasive treatment option for only a small 
group of patients. Currently, there is a need for non-invasive alternative treatments, 
especially for those patients not eligible for radical surgery. Chapter 7 shows that 
radiotherapy is such an alternative treatment for epilepsy. Due to the excellent 
collaboration between the neurologist, neurosurgeon, neuro-radiologist and -
radiotherapist within the southern part of The Netherlands, and having the best 
radiotherapy techniques, the next logical step will be offering radiotherapy to a 
selected group of epilepsy patient in Maastricht for the first time in the Netherlands.  
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